US20230193315A1 - Methods for using transcription-dependent directed evolution of aav capsids - Google Patents

Methods for using transcription-dependent directed evolution of aav capsids Download PDF

Info

Publication number
US20230193315A1
US20230193315A1 US17/427,513 US202017427513A US2023193315A1 US 20230193315 A1 US20230193315 A1 US 20230193315A1 US 202017427513 A US202017427513 A US 202017427513A US 2023193315 A1 US2023193315 A1 US 2023193315A1
Authority
US
United States
Prior art keywords
seq
aav
cap
aav9
trade
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
US17/427,513
Other languages
English (en)
Inventor
Hiroyuki Nakai
Samuel Huang
Kei Adachi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oregon Health Science University
Original Assignee
Oregon Health Science University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oregon Health Science University filed Critical Oregon Health Science University
Priority to US17/427,513 priority Critical patent/US20230193315A1/en
Assigned to OREGON HEALTH & SCIENCE UNIVERSITY reassignment OREGON HEALTH & SCIENCE UNIVERSITY ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: ADACHI, KEI, HUANG, SAMUEL, NAKAI, HIROYUKI
Publication of US20230193315A1 publication Critical patent/US20230193315A1/en
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/04—Libraries containing only organic compounds
    • C40B40/06—Libraries containing nucleotides or polynucleotides, or derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1082—Preparation or screening gene libraries by chromosomal integration of polynucleotide sequences, HR-, site-specific-recombination, transposons, viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/33—Alteration of splicing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14123—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14142—Use of virus, viral particle or viral elements as a vector virus or viral particle as vehicle, e.g. encapsulating small organic molecule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14145—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/44—Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor

Definitions

  • This disclosure relates to viral vectors used in gene delivery. More specifically, this disclosure relates to a method for transcription-dependent directed evolution and adeno-associated virus (“AAV”) vectors that are selected by using this method.
  • AAV adeno-associated virus
  • AAV vectors are among the most promising for in vivo gene delivery.
  • the usefulness of AAV vectors has been expanded since a number of naturally occurring new serotypes and subtypes were isolated from human and non-human primate tissues. Gao et al., J Virol 78, 6381-6388 (2004) and Gao et al., Proc Natl Acad Sci USA 99, 11854-11859 (2002).
  • AAV serotype 8 AAV8
  • AAV serotype 9 AAV9
  • a proof-of-concept using AAV-mediated gene therapy has been shown in many preclinical animal models of human diseases.
  • Phase I/II clinical studies have shown promising results for the treatment for hemophilia B (Nathwani et al., N Engl J Med 71, 1994-2004 (2014)), lipoprotein lipase deficiency (Carpentier et al., J Clin Endocrinol Metab 97, 1635-1644 (2012)), Leber congenital amaurosis (Jacobson et al., Arch Ophthalmol 130, 9-24 (2012) and Pierce and Bennett, Cold Spring Harb Perspect Med 5, a017285 (2015)), among others (reviewed in Mingozzi and High, Nat Rev Genet 12, 341-355 (2011) and Wang et al., Nat Rev Drug Discov 18, 358-378 (2019)).
  • Cre-dependent library selection takes advantage of the selective ability of Cre recombinase to act on double-stranded DNA, but not single-stranded DNA, in order to invert vector genome DNA containing a primer binding sequence. Inversion of this sequence allows for direction-selective PCR to specifically amplify viral DNA delivered to cells by AAV variants that are able to undergo the late stage of transduction at which double stranded DNA is formed from single-stranded AAV genomes.
  • Cre driver lines facilitates selective expression of Cre recombinase in a cell type-specific manner, allowing for selection of novel AAV variants that efficiently transduce.
  • AAV-PHP.B AAV9 variant
  • Cre-dependent selection allowed the authors to develop an AAV9 variant, AAV-PHP.B, that is capable of 40 times greater transduction than the parental AAV9 following systemic administration in C57BL/6J mice.
  • Deverman et al. Nat Biotechnol 34, 204-209 (2016).
  • the enhancement exhibited by AAV-PHP.B in mice does not translate to the non-human primate context (Matsuzaki et al. 2018 and Hordeaux et al. 2019).
  • the enhancement does not even extend to all commonly used mouse strains (Matsuzaki et al. 2018 and Hordeaux et al. 2019).
  • Cre-dependent selection is not tractable in clinically relevant large animals, including non-human primates, because Cre transgenic animals are not readily available.
  • next-generation selection strategy (3rd Generation) with similar or better selective stringency as that provided by Cre-dependent selection, but without the need for Cre recombinase.
  • TRADE TRAnscription-dependent Directed Evolution system
  • AAV cap gene in the transcription-dependent selection, we express the AAV cap gene as a non-coding antisense mRNA driven by a cell type-specific enhancer-promoter. Recovery of this antisense transcript by RT-PCR allows for stringent recovery of AAV cap genes at the level of vector-mediated mRNA expression in a specific cell type without the use of Cre recombinase.
  • TRADE is a highly flexible system that can be applied in a wide variety of contexts, including the non-human primate context for development of enhanced AAV vectors for clinical gene therapy. Note that the same principle can be used for expressing AAV cap gene in an sense orientation. However, the sense strand approach results in expression of immunogenic capsid proteins in target cells and is therefore less ideal than the antisense strand approach employed by the TRADE system.
  • This disclosure provides a next-generation directed evolution strategy, termed TRAnscription-dependent Directed Evolution (“TRADE”), that selects for AAV capsid transduction at the level of cell type-specific or ubiquitous mRNA expression.
  • TRADE TRAnscription-dependent Directed Evolution
  • the method described herein provides the following advantages over Cre recombination-based AAV targeted evolution (“CREATE”), the most contemporary methods for AAV capsid directed evolution reported in the literature. Deverman et al., Nat Biotech 34, 204-209 (2016). First, the CREATE system requires Cre expression, which can be attained either by exogenously-delivered Cre expression or by the use of Cre-transgenic animals.
  • the TRADE system does not require Cre-transgenic animals; therefore, it can be applied to animals and cultured cells derived from any animal species and can be readily adapted to large animals, including non-human primates.
  • TRADE allows for cell type-specific selection at the level of AAV genome transcription. Therefore, the TRADE system can provide greater selective pressure than the CREATE system.
  • multiple directed evolution schemes e.g., neuron-specific, astrocyte-specific, oligodendrocyte-specific, and microglia-specific
  • AAV capsid library can be integrated into one AAV capsid library and selection for AAV vectors targeting each cell type can be performed in a single animal.
  • any cell type-specific or tissue/organ-specific enhancers/promoters or ubiquitous enhancers/promoters can be readily used for AAV capsid directed evolution aimed at identification of cell type-specific or ubiquitous novel AAV capsids with enhanced potency.
  • the TRADE methodology is not limited to the genus Dependoparvovirus, including the common AAVs that have been used for gene delivery, but can also be applied more broadly to the family Parvoviridae, including in the genera Bocaparvoviruses and Erythroparvoviruses other than AAV (e.g., bocaviruses), and even more broadly to an DNA virus.
  • TRADE technology was used to identify novel AAV vectors that mediate neuronal transduction in the brain following intravenous administration.
  • Application of TRADE in C57BL/6J mice and a rhesus macaque resulted in the identification of new AAV capsids that can transduce neurons more efficiently and more specifically than AAV9 in the mouse and non-human primate brain following intravenous administration.
  • the present disclosure also provides a method to prevent splicing of antisense mRNA of the AAV capsid gene.
  • Antisense pre-mRNA transcribed from the AAV cap gene open reading frame (“ORF”) can be spliced making (a) truncated mRNA species.
  • ORF open reading frame
  • This disclosure provides a novel strategy to prevent splicing of antisense mRNA of the cap gene.
  • TRADE uses antisense mRNA to recover capsid sequence information
  • TRADE using sense strand mRNA i.e., sense strand TRADE
  • sense strand TRADE results in expression of immunogenic capsid proteins in target cells and therefore is presumably less ideal than the antisense strand approach.
  • FIG. 1 An overview of in vivo library selection strategies utilized for directed evolution of the AAV capsid.
  • AAV vector-mediated transduction is a multi-step process that requires the virion to overcome extracellular barriers, bind receptors on the target cell, enter the cell via endocytosis, escape the endosome, traffic to the nucleus, uncoat, achieve a double-stranded DNA configuration, and finally undergo transcription/translation.
  • the earliest strategies for in vivo library selection (1 st Gen) recovered all vector genome DNA from a tissue sample. Theoretically, this strategy would recover both effective AAV variants, as well as AAV variants that mediate some, but not all of the steps required for vector-mediated transgene expression.
  • this strategy would also recover AAV vector genome DNA from AAV vector particles that do not enter cells and stay in the extracellular matrix.
  • screening a diverse library of synthetic AAV variants would lead to a relatively high background recovery of AAV variants that are completely ineffective gene therapy vectors.
  • focusing on a specific cell type requires further processing, such as fluorescence-activated cell sorting (FACS) or laser capture microdissection (LCM).
  • FACS fluorescence-activated cell sorting
  • LCDM laser capture microdissection
  • the second generation of library selection (2 nd Gen) substantially increased selection stringency by utilizing Cre-dependent recovery of only those AAV variants that are able to achieve the double-strand DNA stage of transduction.
  • the third generation of library selection (3 rd Gen) further builds on AAV directed evolution technology by employing transcription-dependent recovery of AAV variants that are able to mediate transgene mRNA expression from a cell type-specific enhancer-promoter, without the requirement of Cre expression.
  • FIG. 2 Principle of TRADE.
  • A A map of the AAV vector genome in a TRADE configuration (AAV-TRADE).
  • a cell type-specific enhancer-promoter is placed in an antisense orientation to drive AAV cap gene transcription expression as antisense mRNA.
  • a polyadenylation signal (pA) derived from the simian virus 40 (SV40) genome is placed within the AAV genome intron in an antisense orientation to terminate antisense AAV cap gene mRNA transcription.
  • the eGFP open-reading frame (ORF) can be placed as depicted to serve as a reporter or facilitate enrichment of transduced cells by FACS; however, such a marker gene is not strictly necessary for TRADE.
  • a ubiquitous promoter such as the CAG promoter can be also used in TRADE in placed of cell type-specific enhancers-promoters to identify AAV capsids that can transduce a variety of cell types.
  • a cell type-specific enhancer-promoter can be placed upstream of the AAV cap gene ORF to drive expression of the AAV cap gene mRNA transcripts in a sense orientation (i.e., sense strand TRADE).
  • sense orientation i.e., sense strand TRADE
  • the AAV2 viral p40 promoter drives cap gene expression (forward transcription) and cell type-specific transcripts are suppressed, leading to successful production of recombinant AAV vectors containing the AAV-TRADE vector genome.
  • the cell type-specific enhancer-promoter is activated, driving expression of eGFP and the antisense cap mRNA sequence, while the transcriptional activity of the p40 promoter remains inactive in transduced cells due to a lack of adenoviral helper functions.
  • the entire cap gene ORF can be recovered by reverse transcription (RT)-PCR using antisense cap gene mRNA as a template that is expressed in a cell type-specific manner.
  • RT reverse transcription
  • recombinant AAV vectors can be produced successfully at high levels even in the presence of antisense mRNA transcripts expressed due to leaky expression from the human synapsin I gene (hSynl) enhancer-promoter in HEK293 cells.
  • hSynl human synapsin I gene
  • recombinant AAV vectors can be produced successfully at high titers even when we use the CAG promoter that drives expression of antisense AAV cap mRNA transcripts at high levels.
  • FIG. 3 Validation of the TRADE system targeting brain neurons.
  • A A map of the AAV-PHP.B-hSynl-GFP-TRADE vector genome.
  • B To verify the TRADE system, this AAV vector genome was packaged into the AAV-PHP.B capsid as a single-stranded DNA genome and the resulting AAV vector was injected into two 8-week-old C57BL/6J mice intravenously at a dose of 3 ⁇ 10 11 vector genomes (vg) per mouse. Brain tissue was harvested 12 days post-injection.
  • the brain tissue from one animal was fixed with 4% paraformaldehyde and used for immunofluorescence microscopy and the brain tissue from the other animal was unfixed and used for molecular analysis of AAV vector genome DNA and RNA.
  • C Immunofluorescence microscopy image of brain sections stained with anti-GFP antibody confirmed expression of the cell type-specific enhancer-promoter-driven transcript.
  • D hSynl enhancer-promoter-driven GFP expression was observed specifically in neurons (anti-HuC/D+).
  • E RT-PCR was used to recover the full-length cap ORF sequence (RT+).
  • RT- a no reverse transcriptase control
  • Plas a positive control obtained with DNA-PCR using a plasmid template containing the AAV-PHP.B-hSynl-GFP-TRADE vector genome sequence
  • NT a no template PCR control.
  • F Sanger sequencing of the RT-PCR product revealed expected splicing of the MVM intron in the antisense transcripts expressed by the hSynl enhancer-promoter (SEQ ID NO:190). The exon-exon junction is highlighted with gray.
  • G Sanger sequencing confirmed the insertion of the PHP.B peptide (highlighted with gray) (SEQ ID NO:191).
  • FIG. 4 Splicing of the antisense mRNA of the AAV9 cap ORF.
  • Two cell lines, HEK293 and Neuro2a were transfected with plasmids containing the AAV9 cap ORF in the TRADE configuration, with or without a GFP reporter. They are indicated as “GFP TRADE” and “TRADE”, respectively, in the figure.
  • Cells were harvested 3 days post-transfection, RNA was extracted, and RT-PCR was performed with a set of PCR primers that amplify the full cap ORF sequence. Instead of recovering the expected amplicon size of 2.4 kb as shown in the positive control (PC) lane, we consistently recovered amplicons of approximately 0.7 kb.
  • PC positive control
  • FIG. 5 An intron identified in antisense mRNA derived from the AAV9 cap gene (SEQ ID NO:192).
  • AAV-PHP.B cap gene sequence was transcribed in an antisense orientation in HEK293 cells or Neuro2a cells under the control of the neuron-specific human synapsin I (hSynl) enhancer-promoter, a splicing event was identified with cryptic splice donor and splice acceptor sites (please refer to FIG. 6 as well).
  • the underlined sequence indicates the intron found within the AAV9 cap ORF. This splicing event was not observed in mouse brain neurons.
  • the hSynl enhancer-promoter has been used as a neuron-specific element, it has been shown to drive leaky expression in HEK293 cells; and (2) the AAV9 cap ORF sequence used for the intron splicing experiment had the following silent mutations near the C-terminus: gaaccccgccccattggcacGCgTtacCTGACTCGTAATCTGTAA (SEQ ID NO:1). The intron sequence is underlined, and the silent mutations that have been introduced into the intron to create an Mlul (ACGCGT) recognition site are indicated in uppercase.
  • FIG. 6 Cryptic splice donor (SD) and splice acceptor (SA) sites with the common features of exon-intron junctions present in the AAV cap ORFs in an antisense orientation.
  • Nucleotide sequences of the cap genes derived from 122 naturally occurring AAV strains (serotypes and variants) are aligned using a multiple sequence alignment program (SEQ ID NO 223-316).
  • SEQ ID NO 223-316 The exon-intron junctions identified in the AAV9 cap ORF-derived antisense mRNA are indicated with solid lines.
  • the dashed line in the splice acceptor region indicates putative splice acceptor sites in the AAV cap ORFs devoid of the splice acceptor AG/TC sequence at the position expected from the sequence conservation.
  • the dashed line in the splice donor region indicates the splice donor site identified in the AAV3 cap ORF-derived antisense mRNA (please refer to FIG. 7 ).
  • the GT/CA splice donor sites and the AG/TC splice acceptor motifs, followed by a stretch of T’s, are the common features of exon-intron junctions and are very well-conserved across many AAV strains.
  • the splice donor and acceptor sites identified in the AAV9 cap ORF shown in this figure have also been identified in the AAV1 cap ORF.
  • serotypes other than AAV1, 3, 5 and 9 splicing events in antisense mRNA of the AAV cap ORFs are currently under investigation.
  • the highlighted variants are common AAV serotypes.
  • FIG. 7 Introns identified in antisense mRNA derived from the AAV3 cap gene.
  • pAAV3-hnLSP-MCS-TRADE2 is a plasmid carrying the wild-type AAV3 cap ORF placed under a liver-specific enhancer-promoter with an MVM intron (hnLSP).
  • the nucleotide sequence of the AAV3 cap ORF is the same as that of the naturally identified AAV3.
  • HepG2 cells, a human hepatoma cell line, were transfected with plasmid pAAV3-hnLSP-MCS-TRADE2.
  • Antisense mRNA derived from the AAV3 cap ORF was then analyzed by RT-PCR.
  • Sequences of two truncated RT-PCR products were determined by Sanger sequencing following blunt-end TOPO cloning of the PCR products, which revealed introns found within the antisense AAV3 cap ORF (Panels A and B, SEQ ID NO:193). Intron sequences are in lowercase letters with underline.
  • the most upstream splice donor site is found to be only 3 bp away from the splice donor site identified in the AAV9 cap ORF, which is indicated in a dashed line in FIG. 6 .
  • the most downstream splice acceptor site is found approximately 80 bp upstream of that of the AAV9 cap ORF. Please note that all the splice donor and acceptor sites identified in the AAV3 cap ORF have also been identified in the AAV1 cap ORF.
  • FIG. 8 Additional cryptic splice acceptor sites present in the AAV cap ORFs.
  • a and B Nucleotide sequences of the cap genes derived from 122 naturally occurring AAV strains (serotypes and variants) are aligned using a multiple sequence alignment program (SEQ ID NO:317-420). The exon-intron junctions at the splice acceptor sites identified in the AAV3 cap ORF-derived antisense mRNA are indicated with solid thin lines. The dashed line in Panel A indicates alternative putative splice acceptor sites near the experimentally determined splice acceptor site.
  • the AG/TC splice acceptor sites, followed by a stretch of T’s, are a common feature of exon-intron junctions at splice acceptor sites and are very well conserved across many AAV strains.
  • the AAV3 cap ORF is highlighted.
  • the splice acceptor sites identified in the AAV3 cap ORF shown in Panels A and B have also been identified in the AAV1 cap ORF.
  • As for the AAV5 cap ORF no splicing events have been observed at any sites in antisense mRNA transcription. For serotypes other than AAV1, 3, 5 and 9, splicing events in antisense mRNA of the AAV cap ORFs are currently under investigation.
  • FIG. 9 Additional potential splice donor sites present in the AAV cap ORFs. Nucleotide sequences of the cap genes derived from 122 naturally occurring AAV strains (serotypes and variants) are aligned using a multiple sequence alignment program (SEQ ID NO:421-461). The exon-intron junctions at the splice donor sites identified in the AAV3 cap ORF-derived antisense mRNA are indicated with a solid line. The GT/CA splice donor consensus sequence at this position is retained by only half of AAV strains. This splice donor site has been identified in the AAV1 cap ORF.
  • FIG. 10 Splice donor and splice acceptor sites identified in the AAV1 cap ORF.
  • the nucleotide sequence of the AAV1 cap ORF is shown (SEQ ID NO:194).
  • the AAV1 cap ORF was expressed by the hSynl enhancer-promoter in human embryonic kidney (HEK) 293 cells or Neuro2a cells in an antisense orientation.
  • Antisense mRNA derived from the AAV1 cap ORF was then analyzed by RT-PCR. Sequences of RT-PCR products were determined by Sanger sequencing following blunt-end TOPO cloning of the PCR products, which revealed introns found within the AAV1 cap ORF.
  • Exon-intron junctions identified in antisense AAV1 cap mRNA are indicated with AG/TC for the splice donor sites and GT/CA for the splice acceptor sites.
  • AG/TC and GT/CA in uppercase are the consensus two nucleotides at the 5′ end and the 3′ end of an intron, respectively. Since the splicing occurs in antisense mRNA of the ORF, intron sequences are between CT (splice acceptor) and AC (splice donor) in various combinations in the above sequence. The detailed information about the observed combinations of the splice donors and acceptors is not shown.
  • CT or AC The two conserved nucleotides at exon-intron junctions indicated in boldface are those that are highly conserved across different AAV serotypes.
  • CT or AC The two conserved nucleotides at exon-intron junctions (CT or AC) that are underlined are those that have also been identified in antisense AAV3 or AAV9 cap mRNA transcripts.
  • FIG. 11 Splicing-suppressing mutagenesis of the AAV9 cap ORF.
  • Silent mutations are introduced around the splice acceptor (SA) site and/or the splice donor (SD) site in the AAV9 cap ORF to suppress the splicing observed on the antisense mRNA transcripts.
  • the spliced-out intron from the native sequence (SEQ ID NO:195, SEQ ID NO:196) is indicated with underlines.
  • the AAV9NS1 genome (SEQ ID NO:197) has a set of mutations around the SA site while the AAV9NS2 genome (SEQ ID NO:198) has a set of mutations around the SD site.
  • the AAV9NS3 genome has both sets of mutations. The numbers to the right indicate the nucleotide position relative to the first nucleotide of the AAV9 cap ORF.
  • FIG. 12 Mutations introduced around the splice donor and/or accepter site(s) effectively suppress the splicing of antisense mRNA derived from the AAV9 cap ORF.
  • Neuro2a cells were transfected with plasmids containing the AAV9 cap ORF and various potentially splicing-suppressing mutations in the TRADE configuration (NS1-3).
  • RNA was harvested 3 days post-transfection and RT-PCR was performed with a set of PCR primers that can recover the full cap ORF sequence. In stark contrast to results seen in FIG. 4 , full-length amplicons were successfully recovered.
  • NS1 the AAV9-TRADE vector genome with a codon-modified splice acceptor.
  • NS2 the AAV9-TRADE vector genome with a codon-modified splice donor.
  • NS3 the AAV9-TRADE vector genome with codon-modified splice acceptor and splice-donor.
  • PC a positive control using a plasmid template containing the AAV-PHP.B-hSynl-GFP-TRADE vector genome sequence; NC, a no template PCR control.
  • FIG. 13 Study design for application of TRADE to identify enhanced AAV variants for brain neuron transduction following systemic AAV vector injection.
  • A A map of the AAV9-N272A-hSynl-GFP-TRADE-PepLib vector genome. The hSynl enhancer-promoter is utilized to drive expression specifically in neurons.
  • the liver-detargeted AAV9-N272A cap (PCT/US2017/068050) serves as the platform for AAV library generation.
  • a randomized 8 amino acid peptide encoded by (NNK) 8 and flanked by glycine-serine linkers (SEQ ID NO:2) was substituted for Q588 of the AAV9-N272A cap sequence (SEQ ID NO:222).
  • the plasmid library was used to produce an AAV library using a triple transfection protocol.
  • the library was purified through PEG precipitation and two rounds of CsCI ultracentrifugation, then injected via tail vein at a dose of 3 x 10 11 vg/mouse. Brain tissue was harvested 12 days post-injection. RNA was recovered using TRIzol and RT-PCR was used to recover a fragment of cap containing the peptide insertion, which was subsequently cloned back into the AAV vector plasmid backbone. This was repeated for 3 rounds of selection in C57BL/6J mice. In parallel, a single round of selection was performed in rhesus macaque using a dose of 2.7 x 10 12 vg/kg.
  • FIG. 14 Validation of neuronal transduction of the 26 novel AAV capsids in mice and a nonhuman primate by AAV RNA Barcode-Seq.
  • A A map of the double-stranded (ds) AAV-hSynl-GFP-BC vector.
  • a pair of two 12 nucleotide-long DNA barcodes (VBCx-L and VBCx-R) are placed under the human synapsin I (hSynl) gene enhancer-promoter.
  • VBCx-L and VBCx-R The human synapsin I gene enhancer-promoter.
  • VBCs virus barcodes
  • a DNA/RNA-barcoded dsAAV-hSynl-GFP-BC library (dsAAV-hSynl-GFP-BCLib) containing 26 novel AAV variants identified by TRADE (5 variants identified by TRADE in mice and 21 variants identified by TRADE in a non-human primate) and control AAV capsids (AAV9, AAV9-N272A and AAV-PHP.B) was injected intravenously into three adult male C57BL/6J mice and three adult male BALB/cJ mice at a dose of 5 x 10 11 vg per mouse. Two weeks post-injection, various tissues were harvested and analyzed for transduction at AAV vector genome transcripts levels by AAV RNA Barcode-Seq.
  • Transduction levels are expressed as phenotypic difference (PD) values relative to the reference control, AAV9.
  • PD phenotypic difference
  • AAV capsid amino acid sequence information of the HN1 to HN26 variants please refer to Table 3.
  • C Neuronal transduction of the 26 novel AAV variants and 3 control AAV capsids in the hippocampus of a rhesus macaque. The same DNA/RNA-barcoded AAV library was injected intravenously into one juvenile male rhesus macaque at a dose of 2 ⁇ 10 13 vg/kg. Two weeks post-injection, various brain regions were harvested and analyzed for transduction by AAV RNA Barcode-Seq.
  • FIG. 15 Validation of enhanced neuronal transduction of AAV9-N272A-HN1 in mice using conventional eGFP reporter vectors and histological quantification.
  • mice were transcardially perfused with 4% paraformaldehyde and brain tissue was processed for immunohistochemistry.
  • A A map of the self-complementary hSynl-eGFP vector genome.
  • B Representative tilescan images of sagittal sections stained with anti-GFP antibody.
  • C Quantification of neuronal transduction in (B) based on automated counts of cells expressing eGFP and NeuN in four brain regions.
  • E Quantification of neuronal transduction in (D) based on hand counts of cells expressing eGFP and NeuN by a blinded observer. Error bars represent mean +/- SEM. ***p ⁇ 0.001.
  • FIG. 16 Validation of enhanced AAV9-N272A-HN1 transduction relative to AAV9 in rhesus macaques using epitope-tagged eGFP reporter vectors.
  • AAV-CAG-nlsGFP vectors used for this study. We produced 4 AAV vectors: AAV9-CAG-FLAGnlsGFP-BCLib, AAV9-CAG-HAnlsGFP-BCLib, AAV9-N272A-HN1-CAG-FLAGnlsGFP-BCLib and AAV9-N272A-HN1-CAG-HAnlsGFP-BCLib.
  • nlsGFP eGFP with the nuclear localization signal derived from the SV40 large T antigen
  • Each vector was a DNA/RNA-barcoded library containing an approximately 1 to 1 mixture of 9 different DNA/RNA-barcoded viral clones; however, this feature was not used in this study.
  • the two vectors in the top half depicted in Panel A were mixed at a ratio of 1:1 to make AAV Library 1 (AAVLib1) and the two vectors in the bottom half were mixed at a ratio of 1:1 to make AAV Library 2 (AAVLib2).
  • AAVLib1 and AAVLib2 each contain AAV9 and AAV9-N272A-HN1 vectors expressing epitope-tagged nlsGFP at a ratio of 1:1, but the capsid-epitope relationship is inverted in order to avoid potential antibody bias in downstream analyses.
  • B Representative tile-scanned brain section from one animal receiving AAVLib. Each AAV library was administered intravenously into a juvenile rhesus macaque at a dose of 3 x 10 13 vg/kg. Tissue was harvested 3-weeks post-injection, cut into 4 mm slabs, fixed in 4% paraformaldehyde, and processed for immunohistochemical analysis with anti-GFP, anti-FLAG and anti-HA antibodies.
  • eGFP expression indicates that a cell was transduced by either AAV9 or AAV9-N272A-HN1 or both.
  • FLAG staining indicates that the AAV9 capsid mediated transduction
  • HA staining indicates that AAV9-N272A-HN1 mediated transduction.
  • Top-right inset motor cortex; bottom-right inset, putamen. This experiment revealed that AAV9-N272A-HN1 transduced the brain cells better than AAV9 by several fold with strong neuronal tropism compared to AAV9. Therefore, as far as neuronal transduction is concerned, AAV9-N272A-HN1 mediates much higher neuronal transduction than AAV9.
  • FIG. 17 Biodistribution of AAV9-N272A-HN1 to major peripheral organs following systemic delivery in mice and rhesus macaques.
  • AAV DNA Barcode-Seq to determine relative abundance of AAV vector genome DNAs in each peripheral organ, delivered by each AAV capsid contained in the dsAAV-hSynl-GFP-BCLi b library (Panels A, B and C).
  • the dsAAV-hSynl-GFP-BCLib library contained 26 AAV variants identified by TRADE in mice and in a non-human primate together with the controls, AAV9, AAV9-N272A and AAV-PHP.B.
  • DNA was extracted from various tissues following administration of the dsAAV-hSynl-GFP-BCLi b library (see Table 3) and subjected to AAV DNA Barcode-Seq analysis.
  • A Biodistribution of AAV9, AAV9-N272A, AAV-PHP.B, and TRADE variants to the liver, relative to AAV9, in C57BL/6J mice, BALB/cJ mice and rhesus macaques.
  • AAV DNA Barcode-Seq analysis was performed on the samples collected from one rhesus macaque injected with the dsAAV-hSynl-GFP-BCLib library shown in FIG. 14 D .
  • (D) Biodistribution of AAV9-N272A-HN1 to major peripheral organs besides the liver in rhesus (n 2) based on ssAAV-CAG-nlsGFP-BC analysis.
  • AAV RNA Barcode-Seq analysis was performed on the samples collected from rhesus macaques injected with the ssAAV-GAG-nlsGFP-BCLib vectors shown in FIG. 16 A . Error bars represent mean +/- SEM.
  • AAV9-N272A-HN1 capsid transduced peripheral organs to a lesser degree compared to AAV9 capsid.
  • FIG. 18 AAV9-N272A-HN1 is highly neurotropic following systemic administration in mice.
  • AAV9 and AAV9-N272A-HN1 vectors expressing nlsGFP under the control of the strong, ubiquitous CAG promoter were injected intravenously into 8-week old male BALB/cJ mice at a dose of 3 x 10 11 vg/mouse. Tissues were harvested 12 days post-injection and analyzed by immunostaining with anti-GFP and anti-NeuN antibodies.
  • ss A map of the single-stranded (ss) AAV-CAG-nlsGFP vector genomes used in this study.
  • C Neuronal specificity of AAV9 and AAV9-N272A-HN1 capsids. Quantification of neuronal specificity was determined by dividing the number of double-positive cells (eGFP+/NeuN+) by the total number of GFP+ cells. AAV9-N272A-HN1 is highly specific to neurons (96%) compared to AAV9 (56%).
  • the present disclosure provides a TRADE system that allows directed evolution of the AAV capsid using antisense mRNA of the cap ORF expressed in a cell type-specific or ubiquitous manner.
  • a TRADE system that allows directed evolution of the AAV capsid using antisense mRNA of the cap ORF expressed in a cell type-specific or ubiquitous manner.
  • Such a system does not require Cre-transgenic animals. Therefore, it can be applied to cell type-specific AAV capsid evolution in large animals, including non-human primates, for which Cre-transgenic strains are not readily available.
  • Any cell type-specific or tissue/organ-specific enhancers/promoters or ubiquitous enhancers/promoters can be readily applied to the system with no requirement of transgenesis.
  • the cell type-specific selection is given at the mRNA level.
  • multiple directed evolution schemes may be combined into one directed evolution scheme.
  • selection of neuron-specific AAV capsids, astrocyte-specific AAV capsids, oligodendrocyte-specific AAV capsids and microglia-specific AAV capsids based on cell type-specific transgene mRNA expression can be performed simultaneously in a single animal.
  • the present disclosure provides a sense strand TRADE system that allows directed evolution of the AAV capsid using mRNA of the cap ORF expressed in a cell type-specific or ubiquitous manner that is capable of expressing AAV capsid proteins in target cells.
  • the sense strand TRADE has the same advantages of those antisense strand TRADE presented with data here in that it does not require Cre-transgenic animals, cell type-specific selection is given at the mRNA level, and it is capable of combining multiple directed evolution schemes into one directed evolution round done in a single animal.
  • the possible disadvantage is that immunogenic AAV capsid proteins may be unavoidably expressed persistently in target cells, which may result in undesired consequences in the capsid selection process.
  • the present disclosure also provides novel AAV capsids.
  • these novel AAV capsids can transduce brain neurons several times better than AAV9 in C57BL/6J mice following intravenous injection.
  • the novel AAV capsids transduced up to 8 times better than AAV9 in C57BL/6J mice following intravenous injection.
  • the neuronal transduction levels may be greatly enhanced compared to AAV9 although they may not attain the levels obtained with AAV PHP.B.
  • the novel AAV capsids may transduce brain neurons more efficiently than AAV PHP.B.
  • this disclosure provides novel AAV capsids that can transduce brain neurons several times better than AAV9 following intravenous injection in BALB/cJ mice.
  • the novel AAV capsids can transduce brain neurons up to 7 times better than AAV9 following intravenous injection in BALB/cJ mice.
  • the transduction levels are much higher than AAV PHP.B.
  • this disclosure provides novel AAV capsids that can transduce brain neurons several times better than AAV9 in rhesus macaques following intravenous injection.
  • the novel AAV capsids can transduce brain neurons up to 4 times better than AAV9 in rhesus macaques following intravenous injection. These transduction levels are better than AAV PHP.B.
  • the disclosure provides AAV capsids that can transduce the pulmonary cells with neuronal cell marker expression several times better than AAV9. In certain embodiments, the AAV capsids can transduce such cells up to 17 times better than AAV9.
  • the novel AAV capsids exhibit a liver-detargeting phenotype.
  • the disclosure provides codon-modified AAV cap sequences that are not spliced when expressed in an antisense direction.
  • unmodified AAV cap ORFs are spliced when expressed in an antisense direction (e.g., AAV1, AAV3 and AAV9).
  • some of the codon-modified AAV cap ORFs described in this disclosure are not spliced.
  • the use of such non-spliced cap ORFs may be used for directed evolution using the TRADE system when mutagenesis of the cap gene takes place over a wide region of the cap ORF.
  • AAV vector means any vector that comprises or derives from components of AAV and is suitable to infect mammalian cells, including human cells, of any of a number of tissue types, such as brain, heart, lung, skeletal muscle, liver, kidney, spleen, or pancreas, whether in vitro or in vivo.
  • AAV vector may be used to refer to an AAV type viral particle (or virion) comprising at least a nucleic acid molecule encoding a protein of interest.
  • the AAVs disclosed herein may be derived from various serotypes, including combinations of serotypes (e.g., “pseudotyped” AAV) or from various genomes (e.g., single-stranded or self-complementary).
  • the AAV vectors disclosed herein may comprise desired proteins or protein variants.
  • a “variant” as used herein refers to an amino acid sequence that is altered by one or more amino acids.
  • the variant may have “conservative” changes, wherein a substituted amino acid has similar structural or chemical properties, e.g., replacement of leucine with isoleucine.
  • a variant may have “nonconservative” changes, e.g., replacement of a glycine with a tryptophan.
  • Analogous minor variations may also include amino acid deletions or insertions, or both.
  • Nucleotide sequences such as polynucleotides, encoding proteins of the present disclosure are provided herein.
  • the nucleotides of the present disclosure can be composed of either RNA or DNA.
  • the disclosure also encompasses those polynucleotides that are complementary in sequence to the polynucleotides disclosed herein.
  • references to “essentially the same sequence” refers to one or more sequences that encode amino acid substitutions, deletions, additions, or insertions that do not eliminate the detectability of the polypeptide encoded by the polynucleotides of the present disclosure.
  • variants of the polynucleotides and polypeptides disclosed herein include those sequences wherein one or more peptides or nucleotides of the sequence have been substituted, deleted, and/or inserted.
  • Polynucleotide and polypeptide sequences of the current disclosure can also be defined in terms of particular identity and/or similarity with certain polynucleotides and polypeptides described herein.
  • sequence identity will typically be greater than 60%, preferably greater than 75%, more preferably greater than 80%, even more preferably greater than 90%, and can be greater than 95%.
  • the identity and/or similarity of a sequence can be 49%, 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical as compared to a sequence disclosed herein.
  • Methods of producing AAV vectors as disclosed herein are well known in the art, including methods, for example, of using packaging cells, auxiliary viruses or plasmids, and/or baculovirus systems. See, e.g., Samulski et al., J. Virology 63, 3822 (1989); Xiao et al., J. Virology 72, 2224 (1998); Inoue et al., J. Virology 72, 7024 (1998); WO1998/022607; and WO2005/072364.
  • AAV vectors may be prepared or derived from various serotypes of AAVs which may be mixed together or mixed with other types of viruses to produce chimeric (e.g., pseudotyped) AAV viruses.
  • the AAV vector may be a human serotype AAV vector.
  • a human AAV may be derived from any known serotype, e.g., from any one of serotypes 1-11, for instance from AAV1, AAV2, AAV4, AAV6, or AAV9.
  • the AAV vectors disclosed herein may include a nucleic acid encoding a protein of interest.
  • the nucleic acid also may include one or more regulatory sequences allowing expression and, in some embodiments, secretion of the protein of interest, such as e.g., a promoter, enhancer, polyadenylation signal, an internal ribosome entry site (“IRES”), a sequence encoding a protein transduction domain (“PTD”), a 2A peptide, and the like.
  • the nucleic acid may comprise a promoter region operably linked to the coding sequence to cause or improve expression of the protein of interest in infected cells.
  • Such a promoter may be ubiquitous, cell- or tissue-specific, strong, weak, regulated, chimeric, etc., for example, to allow efficient and stable production of the protein in the infected tissue.
  • the promoter may be homologous to the encoded protein, or heterologous, although generally promoters of use in the disclosed methods are functional in human cells.
  • Examples of regulated promoters include, without limitation, Tet on/off element-containing promoters, rapamycin-inducible promoters, tamoxifen-inducible promoters, and metallothionein promoters.
  • Other promoters that may be used include promoters that are tissue specific for tissues such as kidney, spleen, and pancreas.
  • ubiquitous promoters include viral promoters, particularly the CMV promoter, the RSV promoter, the SV40 promoter, etc., and cellular promoters such as the phosphoglycerate kinase (PGK) promoter and the ⁇ -actin promoter.
  • viral promoters particularly the CMV promoter, the RSV promoter, the SV40 promoter, etc.
  • cellular promoters such as the phosphoglycerate kinase (PGK) promoter and the ⁇ -actin promoter.
  • PGK phosphoglycerate kinase
  • one or more feedback elements may be used to dampen over-expression of the protein of interest.
  • some embodiments of the AAV vectors may include one or more siRNA sequences that would target the exogenous transcript.
  • the AAV vector may include one or more additional promoters that may be recognized by inhibitory transcription factors.
  • the AAV vectors disclosed herein may comprise a construct that may create a homoeostatic feedback loop that may maintain expression levels of the protein of interest at a physiological level.
  • genome editing machinery may be used to genetically modify cellular genome DNA or mRNA transcripts at a site-specific manner.
  • some embodiments of the AAV vectors may include a CRISPR-associated enzyme such as Cas9, a DNA base editor, an RNA editase and/or guide RNA (gRNA) to modify nucleic acid in cells in a site-specific manner.
  • AAV vectors may contain a homology repair template (HDR) for genome editing.
  • HDR homology repair template
  • the AAV vectors disclosed herein can comprise a nucleic acid that may include a leader sequence allowing secretion of the encoded protein.
  • fusion of the transgene of interest with a sequence encoding a secretion signal peptide may allow the production of the therapeutic protein in a form that can be secreted from the transduced cell.
  • secretion signal peptides include the albumin, the ⁇ -glucuronidase, the alkaline protease or the fibronectin secretory signal peptides.
  • peripheral administration of certain AAV vectors, such as a non-AAV9 vector with AAV9 sequences.
  • AAV vectors such as a non-AAV9 vector with AAV9 sequences.
  • peripheral administration may include any administration route that does not necessitate direct injection into brain, heart, lung, skeletal muscle, kidney, spleen, or pancreas. More particularly, peripheral administration may include systemic injections, such as intramuscular, intravascular (such as intravenous,) intraperitoneal, intra-arterial, or subcutaneous injections.
  • peripheral administration also may include oral administration (see, e.g., WO96/40954), delivery using implants, (see, e.g., WO01/91803), or administration by instillation through the respiratory system, e.g., using sprays, aerosols or any other appropriate formulations.
  • oral administration see, e.g., WO96/40954
  • implants see, e.g., WO01/91803
  • administration by instillation through the respiratory system e.g., using sprays, aerosols or any other appropriate formulations.
  • the desired doses of the AAV vectors may be adapted by the skilled artisan, e.g., depending on the disease condition, the subject, the treatment schedule, etc.
  • from 10 5 to 10 12 viral genomes are administered per dose, for example, from 10 6 to 10 11 , from 10 7 to 10 11 , or from 10 8 to 10 11 .
  • exemplary doses for achieving therapeutic effects may include virus titers of at least about 10 5 , 10 6 , 10 7 , 10 8 , 10 9 , 10 10 or 10 11 viral genomes or more.
  • Virus titer may also be expressed in terms of transducing units, which may be readily calculated by those of skill in the art.
  • the AAV vectors disclosed herein may be administered in any suitable form, for instance, either as a liquid solution or suspension, as a solid form suitable for solution or suspension in liquid prior to injection, as a gel or as an emulsion.
  • the vectors may be formulated with any appropriate and pharmaceutically acceptable excipient, carrier, adjuvant, diluent, etc.
  • a suitable carrier or diluent may be an isotonic solution, a buffer, sterile and pyrogen-free water, or, for instance, a sterile and pyrogen-free phosphate-buffered saline solution.
  • the carrier may be in particulate form.
  • the vectors may be administered in a “therapeutically-effective” amount, e.g., an amount that is sufficient to alleviate (e.g., decrease, reduce) at least one of the symptoms associated with a disease state, or to provide improvement in the condition of the subject.
  • repeated administrations may be performed, for instance using the same or a different peripheral administration route and/or the same vector or a distinct vector.
  • the TRADE system utilizes a plasmid construct containing an overlapping bicistronic AAV genome flanked by ITR sequences ( FIG. 2 A ).
  • the AAV2 p40 promoter drives expression of the AAV cap gene to facilitate efficient production of viral particles ( FIG. 2 B ).
  • a cell type-specific enhancer-promoter e.g. the human synapsin I (hSynl) enhancer-promoter drives expression of transcripts encoding GFP and the antisense cap sequence ( FIG.
  • poly A polyadenylation signal embedded in the intron present in the AAV2 genome.
  • TRADE construct as a cloning backbone, we generated an AAV library based on the liver-detargeted AAV9-N272A (PCT/US2017/068050) cap gene platform that contained random 8-mer peptides with glycine-serine linkers (5′-GGGS; 3′-GGGGS) substituted at the position Q588 in the AAV9 capsid.
  • glycine-serine linkers 5′-GGGS; 3′-GGGGS
  • This method ensures that recovered sequences are only derived from AAV variants that are capable of mediating RNA expression in infected cells of our interest.
  • the hSynl enhancer-promoter is used, only sequences of AAV capsids that are capable of transducing neurons can be retrieved, thus enabling neuron-specific selection of AAV capsids.
  • FIG. 3 We first tested the ability of the TRADE system to recover the sequence of the AAV cap gene from cell type-specific antisense mRNA using an AAV-PHP.B-hSynl-GFP-TRADE vector ( FIG. 3 ).
  • a hSynl enhancer-promoter-driven GFP expression cassette was incorporated in the AAV-PHP.B capsid gene-containing AAV vector genome in the TRADE configuration ( FIG. 3 A ). This vector genome was packaged into the AAV-PHP.B capsid, and the resulting AAV vector was injected intravenously into two 8-week-old male C57BL/6J mice ( FIG. 3 B ). Twelve days after injection, brain tissue was harvested.
  • FIGS. 3 C and 3 D Tissue fixed with 4% paraformaldehyde was analyzed by immunofluorescence microscopy. Unfixed tissue was utilized for RNA extraction and RT-PCR analysis. We confirmed that eGFP was expressed only in neurons ( FIGS. 3 C and 3 D ), indicating that the antisense mRNA transcribed from the cap gene is expressed in a cell type-specific manner. We recovered antisense mRNA of the cap gene efficiently by RT-PCR ( FIG. 3 E ). Sanger sequencing of a splice junction unique to the antisense mRNA confirmed that RT-PCR products were indeed derived from the hSynl enhancer-promoter-driven antisense mRNA ( FIG. 3 F ).
  • AAV9-N272A-hSynl-GFP-TRADE-Lib library composed of AAV9-derived mutant capsids that have a GGGS(N 8 )GGGGS (SEQ ID NO:2) peptide insertion at the position of Q588 where N 8 represents a random 8-mer peptide encoded by (NNK) 8 .
  • N 8 represents a random 8-mer peptide encoded by (NNK) 8 .
  • Q588 was substituted with each peptide sequence.
  • the diversity of the AAV library was at least 10 7 .
  • mice directed evolution experiment we infused the AAV library via the tail vein at a dose of 3 x 10 11 vector genomes (vg) per mouse.
  • the AAV library for the second round of selection, we injected the AAV library at a dose of 1 ⁇ 10 12 , 1 ⁇ 10 11 , 1 ⁇ 10 10 , or 1x10 9 vector genomes (vg) using two mice.
  • the AAV library for the third round of selection, we injected the AAV library at a dose of 1 ⁇ 10 11 vg using two mice.
  • RNA was extracted total RNA from the cerebrum, reverse-transcribed the RNA using an oligo dT primer, and amplified the peptide region including the flanking regions by a pair of the cap gene-specific PCR primers.
  • the RT-PCR products were then used to create the next AAV9-N272A-hSynl-TRADE-Lib plasmid library, which was subsequently used to produce the next AAV9-N272A-hSynl-TRADE-Lib virus library.
  • we packaged an AAV9-N272A-hSynl-TRADE-Lib genome was devoid of the GFP ORF.
  • RNAlater Thermo Fisher Scientific
  • HNx designation please refer to Table 3.
  • AAV9-N272A-TTNLAKNS HN1
  • AAV9-N272A-QQNGTRPS HN2
  • AAV9-N272A-TTNLAKNS HN1 transduced the non-human primate brain best in multiple brain regions ( FIGS. 14 C and 14 D ).
  • All of the AAV9-N272A-derived variants including HN1, HN2 and HN3 showed varying degrees of liver-detargeting properties in mice and rhesus macaques ( FIG. 17 A ).
  • AAV9-N272A-TTNLAKNS (HN1) and AAV9-N272A-QQNGTRPS (HN2) can transduce cells with the hSynl enhancer-promoter transcriptional activity in the lung up to 17 times better than AAV9 in mice ( FIG. 17 B , Tables 4 and 6).
  • AAV9-N272A-TTNLAKNS (HN1) exhibits vector genome dissemination to peripheral organs to a lesser degree compared to AAV9 ( FIGS. 17 C and 17 D ).
  • the AAV Barcode-Seq data are summarized in Tables 4 to 9. Representative data presented in Tables 4 to 9 are also shown in a graph format in FIG. 14 and FIG. 17 .
  • the numbers in parentheses indicate the frequency of each peptide among a total of 69 peptides identified after the three round of selection. Peptides with no number were found only once.
  • the sequences of the peptide region were determined by Sanger sequencing. Actual peptide sequences were randomized octapeptides flanked by glycine-serine linkers such that position Q588 was substituted with GGGS(N 8 )GGGGS. For example, “-TNHQSAGGGSTTNLAKNSGGGGSAQAQTG-” for TTNLAKNS and “-TNHQSAGGGSQQNGTRPSGGGGSAQAQTG-” for QQNGTRPS.
  • Each recovered AAV variant was assigned an abbreviation, HNx.
  • a DNA/RNA-barcoded dsAAV-hSynl-GFP-BCLib library containing was constructed such that each AAV variant packaged a unique dsAAV-hSynl-GFP-BC viral genome expressing AAV variant-specific RNA barcodes.
  • the number of unique AAV barcode clones for each variant, including critical reference variants, is presented in this table.
  • SEQ ID AAV serotype SD or SA Exon-intron junction sequence (Introns are underlined) SEQ ID NO:199 AAV1 SD 1009-CTTACCAGCA-1018 SEQ ID NO:199 AAV3 SD 1006-CTTACCAGCA-1015 SEQ ID NO:200 AAV1 SD 1228-TTTACCTTCA-1237 SEQ ID NO:201 AAV3 SD 1237-TATACCTTCG-1246 SEQ ID NO:202 AAV1 SD 1331-ATTACCTGAA-1340 SEQ ID NO:203 AAV1 SD 1434-GCTACCTGGA-1443 SEQ ID NO:204 AAV1 SD 1502-TTTACCTGGA-1510 SEQ ID NO:205 AAV1 SD 1803-ATTACCTGGC-1812 SEQ ID NO:206 AAV3 SD 1803-CTTACCTGGC-1812 SEQ ID NO:207 AAV1 SD 1835-TGTACCTGCA-1844 SEQ ID NO:199 AAV1 SD 1009-CTTACCAGCA-1018 SEQ ID NO:199 AAV3 SD
  • GT splice donor
  • AG splice acceptor
  • the TRADE method described herein uses antisense mRNA for viral protein evolution to establish the proof-of-principle and to show successful reduction of the method to practice.
  • the TRADE system can also utilize mRNA in a sense orientation as long as the viruses can be produced and potential expression of viral proteins in target cells during the directed evolution procedure does not hinder successful evolution of novel capsids.
  • nucleic acid splicing and AAV Additional information related to nucleic acid splicing and AAV may be found in Desmet et al., Nucleic Acids Res 37, e67 (2009); Matsuzaki et al., Neurosci Lett 665, 182-188 (2016); and Hordeaux et al., Mol Ther26, 664-668 (2016).

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Analytical Chemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
US17/427,513 2019-01-31 2020-01-31 Methods for using transcription-dependent directed evolution of aav capsids Pending US20230193315A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US17/427,513 US20230193315A1 (en) 2019-01-31 2020-01-31 Methods for using transcription-dependent directed evolution of aav capsids

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962799603P 2019-01-31 2019-01-31
PCT/US2020/016273 WO2020160508A1 (fr) 2019-01-31 2020-01-31 Méthodes d'utilisation d'une évolution dirigée, dépendant d'une transcription, de capsides aav
US17/427,513 US20230193315A1 (en) 2019-01-31 2020-01-31 Methods for using transcription-dependent directed evolution of aav capsids

Publications (1)

Publication Number Publication Date
US20230193315A1 true US20230193315A1 (en) 2023-06-22

Family

ID=71841691

Family Applications (5)

Application Number Title Priority Date Filing Date
US17/427,513 Pending US20230193315A1 (en) 2019-01-31 2020-01-31 Methods for using transcription-dependent directed evolution of aav capsids
US17/337,341 Active US11459558B2 (en) 2019-01-31 2021-06-02 Methods for using transcription-dependent directed evolution of AAV capsids
US17/822,111 Pending US20230119163A1 (en) 2019-01-31 2022-08-24 Methods for using transcription-dependent directed evolution of aav capsids
US18/160,804 Pending US20230287405A1 (en) 2019-01-31 2023-01-27 Methods for using transcription-dependent directed evolution of aav capsids
US18/160,796 Pending US20230287404A1 (en) 2019-01-31 2023-01-27 Methods for using transcription-dependent directed evolution of aav capsids

Family Applications After (4)

Application Number Title Priority Date Filing Date
US17/337,341 Active US11459558B2 (en) 2019-01-31 2021-06-02 Methods for using transcription-dependent directed evolution of AAV capsids
US17/822,111 Pending US20230119163A1 (en) 2019-01-31 2022-08-24 Methods for using transcription-dependent directed evolution of aav capsids
US18/160,804 Pending US20230287405A1 (en) 2019-01-31 2023-01-27 Methods for using transcription-dependent directed evolution of aav capsids
US18/160,796 Pending US20230287404A1 (en) 2019-01-31 2023-01-27 Methods for using transcription-dependent directed evolution of aav capsids

Country Status (8)

Country Link
US (5) US20230193315A1 (fr)
EP (1) EP3917566A4 (fr)
JP (1) JP2022523719A (fr)
KR (1) KR20210130158A (fr)
CN (1) CN113924115A (fr)
AU (1) AU2020216480A1 (fr)
CA (1) CA3128230A1 (fr)
WO (1) WO2020160508A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113924115A (zh) 2019-01-31 2022-01-11 俄勒冈健康与科学大学 用于aav衣壳的使用转录依赖性定向进化的方法
WO2021202651A1 (fr) * 2020-04-01 2021-10-07 Voyager Therapeutics, Inc. Redirection de tropisme de capsides de vaa
BR112022023106A2 (pt) 2020-05-13 2023-01-17 Voyager Therapeutics Inc Redirecionamento de tropismo de capsídeos de aav
WO2023034775A1 (fr) 2021-08-30 2023-03-09 Avachrome, Inc. Souris knock-out aavr combinée avec le chimérisme hépatique humain et procédés d'utilisation et de production de celle-ci
WO2023060272A2 (fr) * 2021-10-07 2023-04-13 Regenxbio Inc. Virus adéno-associés recombinants pour administration tropique au snc
WO2023183304A2 (fr) * 2022-03-21 2023-09-28 Capsigen Inc. Évolution dirigée transcription-dépendante de capsides d'aav présentant un tropisme amélioré

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5856152A (en) 1994-10-28 1999-01-05 The Trustees Of The University Of Pennsylvania Hybrid adenovirus-AAV vector and methods of use therefor
US6924128B2 (en) * 1994-12-06 2005-08-02 Targeted Genetics Corporation Packaging cell lines for generation of high titers of recombinant AAV vectors
AU707866B2 (en) * 1994-12-06 1999-07-22 Targeted Genetics Corporation Packaging cell lines for generation of high titers of recombinant AAV vectors
US5652224A (en) 1995-02-24 1997-07-29 The Trustees Of The University Of Pennsylvania Methods and compositions for gene therapy for the treatment of defects in lipoprotein metabolism
EP0832266A4 (fr) 1995-06-07 2000-06-28 Univ Yale Administration orale de vecteurs du virus associe a l'adenovirus
US5866552A (en) 1996-09-06 1999-02-02 The Trustees Of The University Of Pennsylvania Method for expressing a gene in the absence of an immune response
AU722375B2 (en) 1996-09-06 2000-08-03 Trustees Of The University Of Pennsylvania, The Methods using cre-lox for production of recombinant adeno-associated viruses
FR2756297B1 (fr) 1996-11-22 1999-01-08 Centre Nat Rech Scient Procede de production de virus recombinants
AU8672198A (en) 1997-07-31 1999-02-22 Chiron Corporation Method enabling readministration of aav vector via immunosuppression of host
US6251677B1 (en) 1997-08-25 2001-06-26 The Trustees Of The University Of Pennsylvania Hybrid adenovirus-AAV virus and methods of use thereof
AU9397098A (en) 1997-09-19 1999-04-12 Trustees Of The University Of Pennsylvania, The Methods and cell line useful for production of recombinant adeno-associated viruses
AU9319198A (en) 1997-09-19 1999-04-05 Trustees Of The University Of Pennsylvania, The Methods and vector constructs useful for production of recombinant aav
US6953690B1 (en) 1998-03-20 2005-10-11 The Trustees Of The University Of Pennsylvania Compositions and methods for helper-free production of recombinant adeno-associated viruses
US6759237B1 (en) 1998-11-05 2004-07-06 The Trustees Of The University Of Pennsylvania Adeno-associated virus serotype 1 nucleic acid sequences, vectors and host cells containing same
JP2002538770A (ja) 1998-11-10 2002-11-19 ユニバーシティ オブ ノース カロライナ アット チャペル ヒル ウイルスベクターとその製造及び投与の方法
US6387368B1 (en) 1999-02-08 2002-05-14 The Trustees Of The University Of Pennsylvania Hybrid adenovirus-AAV virus and methods of use thereof
US6258595B1 (en) 1999-03-18 2001-07-10 The Trustees Of The University Of Pennsylvania Compositions and methods for helper-free production of recombinant adeno-associated viruses
JP4693244B2 (ja) 1999-03-18 2011-06-01 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア 組換えアデノ随伴ウイルスのヘルパー無しの生産のための組成物および方法
US6498244B1 (en) 1999-05-28 2002-12-24 Cell Genesys, Inc. Adeno-associated virus capsid immunologic determinants
WO2001023001A2 (fr) 1999-09-29 2001-04-05 The Trustees Of The University Of Pennsylvania Procedes de modification rapide du peg de vecteurs viraux, compositions servant a ameliorer la transduction de genes, compositions presentant une stabilite physique augmentee, et leurs utilisations
AU2001253255A1 (en) * 2000-04-07 2001-10-23 Large Scale Biology Corporation Compositions and methods for inhibiting gene expression
AU6814901A (en) 2000-06-01 2001-12-11 Univ North Carolina Methods and compounds for controlled release of recombinant parvovirus vectors
US7749492B2 (en) 2001-01-05 2010-07-06 Nationwide Children's Hospital, Inc. AAV vectors and methods
WO2002081711A1 (fr) * 2001-04-06 2002-10-17 Cropdesign N.V. Utilisation de sites de recombinaison doubles et opposes pour le clonage a phase unique de deux segments d'adn
JP4399255B2 (ja) 2001-06-22 2010-01-13 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア 細菌の形質転換体を迅速に選別する方法および新規なサルアデノウイルス蛋白質
CA2455499C (fr) 2001-08-08 2011-06-21 The Trustees Of The University Of Pennsylvania Procede de purification de vecteurs viraux possedant des proteines se liant a l'acide sialique
DK1310571T3 (da) 2001-11-13 2006-06-19 Univ Pennsylvania Fremgangsmåde til identifikation af ukendte adeno-associerede virussekvenser (AAV-sekvenser) og et kit til fremgangsmåden
HU230488B1 (hu) 2001-11-21 2016-08-29 The Trustees Of The University Of Pennsylvania Simian adenovírus nukleinsav és aminosav-szekvencia, azt tartalmazó vektorok, és eljárások annak alkalmazására
EP1463805B1 (fr) 2001-12-17 2014-10-22 The Trustees of The University of Pennsylvania Sequences du serotype 9 du virus associe a l'adenovirus (aav), vecteurs les contenant et utilisations correspondantes
EP1453547B1 (fr) 2001-12-17 2016-09-21 The Trustees Of The University Of Pennsylvania Sequences du serotype 8 du virus associe a l'adenovirus (aav), vecteurs les contenant et utilisations correspondantes
US7235393B2 (en) 2002-04-29 2007-06-26 The Trustees Of The University Of Pennsylvania Method for direct rescue and amplification of integrated viruses from cellular DNA of tissues
ES2629087T3 (es) 2003-06-19 2017-08-07 Genzyme Corporation Viriones de AAV con inmunorreactividad reducida y usos de los mismos
EP1636370B1 (fr) 2003-06-20 2014-04-16 The Trustees of The University of Pennsylvania Procede pour produire des adenovirus chimeriques et utilisations de ces derniers
US9441244B2 (en) 2003-06-30 2016-09-13 The Regents Of The University Of California Mutant adeno-associated virus virions and methods of use thereof
ES2411479T3 (es) 2003-09-30 2013-07-05 The Trustees Of The University Of Pennsylvania Clados de virus adeno-asociados (AAV), secuencias, vectores que los contienen, y usos de los mismos
US20060166363A1 (en) 2004-01-27 2006-07-27 Sergei Zolotukhin Modified baculovirus expression system for production of pseudotyped rAAV vector
WO2006078279A2 (fr) 2004-04-28 2006-07-27 The Trustees Of The University Of Pennsylvania Liberation sequentielle de molecules immunogenes par administrations mediees par un adenovirus ou un virus adenoassocie
EP3085389A1 (fr) 2005-04-07 2016-10-26 The Trustees Of The University Of Pennsylvania Procédé d'augmentation de la fonction d'un vecteur aav
US9150882B2 (en) 2006-01-31 2015-10-06 The Board Of Trustees Of The Leland Stanford Junior University Self-complementary parvoviral vectors, and methods for making and using the same
EP2007795B1 (fr) 2006-03-30 2016-11-16 The Board Of Trustees Of The Leland Stanford Junior University Protéines de capsides aav
WO2007120533A2 (fr) 2006-03-30 2007-10-25 The Board Of Trustees Of The Leland Stanford Junior University Cassette d'expression comportant un minigène
CN101528916B (zh) 2006-04-28 2013-09-04 宾夕法尼亚大学托管会 规模可调的aav生产方法
WO2008024998A2 (fr) * 2006-08-24 2008-02-28 Virovek, Inc. Expression dans des cellules d'insecte de gènes ayant des cadres ouverts de lecture chevauchants, procédés et compositions pour cela
BRPI0819774A2 (pt) 2007-11-28 2014-10-14 Univ Pennsylvania Subfamília c de adenovírus sadv-40, -31 e -34 de símio e seus usos
JP5740157B2 (ja) 2007-11-28 2015-06-24 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア サルサブファミリーＢアデノウイルスＳＡｄＶ−２８、−２７、−２９、−３２、−３３および−３５ならびにそれらの用途
SI2220241T1 (sl) 2007-11-28 2017-02-28 The Trustees Of The University Of Pennsylvania Adenovirus, ki obsega kapsidni heksonski protein opičjega E adenovirusa SAdV-39, in njegove uporabe
EP2250255A2 (fr) 2008-03-04 2010-11-17 The Trustees of the University of Pennsylvania Adénovirus simiens sadv-36, -42.1, -42.2 et -44 et leurs utilisations
JP5809978B2 (ja) 2008-10-31 2015-11-11 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア サルアデノウイルスＳＡｄＶ−４３、−４５、−４６、−４７、−４８、−４９および−５０ならびにそれらの用途
WO2010138675A1 (fr) 2009-05-29 2010-12-02 The Trustees Of The University Of Pennsylvania Adénovirus simien 41 et ses utilisations
US8445454B2 (en) 2009-10-23 2013-05-21 The Board Of Trustees Of The Leland Stanford Junior University Use on minicircle vectors for cardiac gene therapy
WO2011115996A1 (fr) * 2010-03-17 2011-09-22 Anaptysbio, Inc. Procédé de production de produits de la transcription utilisant des sites cryptiques d'épissage
US9315825B2 (en) 2010-03-29 2016-04-19 The Trustees Of The University Of Pennsylvania Pharmacologically induced transgene ablation system
US8628966B2 (en) * 2010-04-30 2014-01-14 City Of Hope CD34-derived recombinant adeno-associated vectors for stem cell transduction and systemic therapeutic gene transfer
EP2634253B1 (fr) * 2010-10-27 2016-05-11 Jichi Medical University Virions de virus adéno-associé pour le transfert de gènes dans des cellules neuronales
WO2012064960A2 (fr) * 2010-11-10 2012-05-18 Fred Hutchinson Cancer Research Center Compositions et procédés pour la génération de vecteurs viraux adénoassociés ayant une contamination indétectable de gènes de capside
EP2643465B1 (fr) 2010-11-23 2016-05-11 The Trustees Of The University Of Pennsylvania Adénovirus simiens de la sous-famille e a1321 et ses utilisations
EP2675902B1 (fr) 2011-02-17 2019-03-27 The Trustees Of The University Of Pennsylvania Compositions et méthodes pour modifier la specificite au tissus et ameliorer le transfert de gene a mediation par aav9
EP3795581A3 (fr) 2011-08-24 2021-06-09 The Board of Trustees of the Leland Stanford Junior University Nouvelles protéines de capside avv pour le transfert d'acides nucléiques
SG11201407343XA (en) 2012-05-18 2014-12-30 Univ Pennsylvania Subfamily e simian adenoviruses a1302, a1320, a1331 and a1337 and uses thereof
WO2014052693A2 (fr) 2012-09-29 2014-04-03 The Trustees Of The University Of Pennsylvania Composition à usage vétérinaire et procédés de stérilisation et de castration non chirurgicaux
PT2984166T (pt) 2013-03-15 2020-07-16 Univ Pennsylvania Composições para tratar mps i
WO2015012924A2 (fr) 2013-04-29 2015-01-29 The Trustees Of The University Of Pennsylvania Cassettes d'expression préférentielle pour tissus modifiées par un codon, vecteurs les contenant, et utilisation
LT3116900T (lt) 2014-03-09 2020-12-10 The Trustees Of The University Of Pennsylvania Kompozicijos, naudotinos ornitino transkarbamilazės (otc) nepakankamumo gydymui
US10612041B2 (en) 2014-03-21 2020-04-07 The Board Of Trustees Of The Leland Stanford Junior University Genome editing without nucleases
US10746742B2 (en) 2014-04-25 2020-08-18 Oregon Health & Science University Methods of viral neutralizing antibody epitope mapping
MX365658B (es) 2014-05-13 2019-06-10 Univ Pennsylvania Composiciones que comprenden virus adenoasociado (aav) que expresa constructos de anticuerpos duales y sus usos.
WO2015191508A1 (fr) 2014-06-09 2015-12-17 Voyager Therapeutics, Inc. Capsides chimériques
RU2716991C2 (ru) 2014-11-05 2020-03-17 Вояджер Терапьютикс, Инк. Полинуклеотиды aadc для лечения болезни паркинсона
IL292999A (en) 2014-11-14 2022-07-01 Voyager Therapeutics Inc Preparations and methods for the treatment of amyotrophic lateral sclerosis
JP6863891B2 (ja) 2014-11-14 2021-04-21 ボイジャー セラピューティクス インコーポレイテッドＶｏｙａｇｅｒ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 調節性ポリヌクレオチド
US10406244B2 (en) 2015-12-02 2019-09-10 The Board Of Trustees Of The Leland Stanford Junior University AAV vectors with expanded packaging capacity
EP3384034B1 (fr) 2015-12-02 2020-07-08 The Board of Trustees of the Leland Stanford Junior University Nouveaux capsides de virus adéno-associés recombinants avec du tropisme pour les muscles sqeletiques humains amélioré
EP3417055B1 (fr) 2016-02-16 2021-10-13 The Board of Trustees of the Leland Stanford Junior University Nouveaux capsides de virus adéno-associés de recombinaison résistants à des anticorps neutralisants humains pré-existants
PT3445773T (pt) 2016-05-13 2023-03-13 4D Molecular Therapeutics Inc Cápsides variantes de vírus adeno-associado e métodos de utilização das mesmas
IL302748A (en) 2016-05-18 2023-07-01 Voyager Therapeutics Inc modulatory polynucleotides
WO2018119330A2 (fr) * 2016-12-22 2018-06-28 Oregon Health & Science University Vecteurs viraux adéno-associés
AU2018350992A1 (en) 2017-10-18 2020-05-21 Regenxbio Inc. Fully-human post-translationally modified antibody therapeutics
JP2021534809A (ja) 2018-10-02 2021-12-16 ボイジャー セラピューティクス インコーポレイテッドVoyager Therapeutics, Inc. Ａａｖカプシドの向性の再指向化
CN113924115A (zh) 2019-01-31 2022-01-11 俄勒冈健康与科学大学 用于aav衣壳的使用转录依赖性定向进化的方法

Also Published As

Publication number Publication date
WO2020160508A8 (fr) 2020-12-17
AU2020216480A1 (en) 2021-09-09
US20230287405A1 (en) 2023-09-14
US11459558B2 (en) 2022-10-04
JP2022523719A (ja) 2022-04-26
US20230287404A1 (en) 2023-09-14
US20230119163A1 (en) 2023-04-20
KR20210130158A (ko) 2021-10-29
EP3917566A1 (fr) 2021-12-08
EP3917566A4 (fr) 2022-10-26
WO2020160508A1 (fr) 2020-08-06
CN113924115A (zh) 2022-01-11
US20210348160A1 (en) 2021-11-11
CA3128230A1 (fr) 2020-08-06

Similar Documents

Publication Publication Date Title
US20230193315A1 (en) Methods for using transcription-dependent directed evolution of aav capsids
US11866462B2 (en) Recombinant adeno-associated viral vectors
US20230048025A1 (en) Adeno associated viral vectors
EP3452495B1 (fr) Polynucléotides, polypeptides et virions de virus adéno-associé
US9677088B2 (en) Adeno associated virus plasmids and vectors
EP2037892B1 (fr) Gènes de facteur viii et de facteur ix modifiés, et vecteurs pour thérapie génique
JP2022062121A (ja) 血友病ａ治療に対する遺伝子療法
CA3054131A1 (fr) Proteines des capsides aav modifiees et leurs utilisations
JP2022544004A (ja) 操作された核酸調節エレメントならびにその使用方法
WO2021084276A2 (fr) Produit de synthèse de facteur viii
WO2013159036A1 (fr) Plasmides et vecteurs de virus associés aux adénovirus
WO2022251096A1 (fr) Séquence de promoteur et produits apparentés et leurs utilisations
TW202417631A (zh) 用ａａｖ基因治療載體治療心肌病
WO2023147304A1 (fr) Capsides d'aav pour une transduction cardiaque améliorée et un ciblage du foie
WO2023147558A2 (fr) Méthodes crispr pour corriger des mutations du gène bag3 in vivo
CN117003833A (zh) 肝脏特异性的腺相关病毒血清型及应用
AU2016202153A1 (en) Vectors with modified initiation codon for the translation of AAV-Rep78 useful for production of AAV in insect cells

Legal Events

Date Code Title Description
AS Assignment

Owner name: OREGON HEALTH & SCIENCE UNIVERSITY, OREGON

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:NAKAI, HIROYUKI;HUANG, SAMUEL;ADACHI, KEI;REEL/FRAME:058397/0534

Effective date: 20200910

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION